Data Synthesis: Cangrelor is a P2Y 12 antagonist under development for treatment of acute coronary syndrome. Cangrelor has been studied as an intravenous infusion in doses of 2 or 4 µg/kg/min.

The “vulnerable plaque” responsible for acute coronary syndromes and, ultimately, coronary artery thrombosis, has a thin cap and a necrotic core (see Atherosclerosis Topic Review). A key ...

Acute coronary syndrome (ACS ... Though ACS is usually associated with coronary thrombosis, it can also be associated with cocaine use. Cardiac chest pain can also be precipitated by anemia ...

Plaque disruption and subsequent thrombosis are recognized as critical processes contributing to the onset of acute coronary ischemic syndromes. Intravascular thrombus adhering to an underlying ...

The algorithm is designed to more quickly and accurately detect Acute Coronary Syndrome or ACS in patients presenting with chest pain, one of the most common reasons for Emergency Department visit.

acute coronary syndrome readmission, blood clotting (stent thrombosis) and bleeding events. Among the 3,974 participants (mean age, 63.4 years; 74.9% male), 21.8% were identified as HBR ...

Albano AJ, Thompson PD, Kapur NK. Acute coronary thrombosis in Boston marathon runners. N Engl J Med. 2012 Jan 12;366(2):184–5 Hull CM, Hopkins CL, Purdy NJ, Lloyd RC, Harris JA. A case of unprovoked ...

A new study could lead to more widespread use of imaging technique to improve survival and prevent complications.